A Phase 2 interventional study of GRT6005 and MS Continus® in Diabetic Polyneuropathy, sponsored by Tris Pharma, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Diabetic Neuropathies with a site in Germany — 3 open to participants now, 3 under way, 2 of them phase 3. Diabetic Neuropathies · Germany.
Among the 37 studies in Diabetic Neuropathies with a site in Germany, this one is the 27th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2009, is one of 14 in phase 2, and was the 15th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →3 of the 37 studies in Diabetic Neuropathies with a site in Germany are open now. Recruiting first, the newest first:
Heinrich-Heine University, Duesseldorf · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 189 across the 35 interventional studies, 61 across the 2 observational. Of the 32 that completed or were terminated, 10 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 37 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 3 studies filed under Diabetic Neuropathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 37 studies in Diabetic Neuropathies with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1, 40 µg
Drug: GRT6005
Dose 2, 120 µg
Drug: GRT6005
Dose 3
Drug: GRT6005
Dose 4
Drug: GRT6005
Dose 5
Drug: GRT6005
Dose 6
Drug: GRT6005
Dose 7
Drug: GRT6005
Morphin
Drug: MS Continus®
Placebo
Drug: Placebo
liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
60 mg, capsule, once daily
liquid formulation and capsule, once daily
Average daily pain intensity
Time frame: 5 days
Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values
Time frame: 5 days
The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol